Clinical NEC prevention practices drive different microbiome profiles and functional responses in the preterm intestine.
Charlotte J NeumannAlexander MahnertChristina KumpitschRaymond KiuMatthew J DalbyMagdalena KujawskaTobias MadlStefan Kurath-KollerBerndt UrlesbergerBernhard ReschLindsay J HallChristine Moissl-EichingerPublished in: Nature communications (2023)
Preterm infants with very low birthweight are at serious risk for necrotizing enterocolitis. To functionally analyse the principles of three successful preventive NEC regimens, we characterize fecal samples of 55 infants (<1500 g, n = 383, female = 22) longitudinally (two weeks) with respect to gut microbiome profiles (bacteria, archaea, fungi, viruses; targeted 16S rRNA gene sequencing and shotgun metagenomics), microbial function, virulence factors, antibiotic resistances and metabolic profiles, including human milk oligosaccharides (HMOs) and short-chain fatty acids (German Registry of Clinical Trials, No.: DRKS00009290). Regimens including probiotic Bifidobacterium longum subsp. infantis NCDO 2203 supplementation affect microbiome development globally, pointing toward the genomic potential to convert HMOs. Engraftment of NCDO 2203 is associated with a substantial reduction of microbiome-associated antibiotic resistance as compared to regimens using probiotic Lactobacillus rhamnosus LCR 35 or no supplementation. Crucially, the beneficial effects of Bifidobacterium longum subsp. infantis NCDO 2203 supplementation depends on simultaneous feeding with HMOs. We demonstrate that preventive regimens have the highest impact on development and maturation of the gastrointestinal microbiome, enabling the establishment of a resilient microbial ecosystem that reduces pathogenic threats in at-risk preterm infants.
Keyphrases
- low birth weight
- preterm infants
- human milk
- preterm birth
- clinical trial
- gestational age
- microbial community
- copy number
- fatty acid
- escherichia coli
- staphylococcus aureus
- climate change
- human health
- genome wide
- pseudomonas aeruginosa
- gene expression
- cancer therapy
- drug delivery
- dna methylation
- antimicrobial resistance
- open label
- single cell
- genome wide identification
- placebo controlled
- phase ii
- infectious diseases